This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G et al. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant (e-pub ahead of print 21 December 2015; doi:10.1038/bmt.2015.319).
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantationfor multiple myeloma. N Engl J Med 2012; 366: 1770–1781.
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.
Bruno B, Rotta M, Patriarca F, Rotta M, Sorasio R, Allione B et al. A comparison of allografting with autografting for newly-diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.
Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914–3915.
Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Non- myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375–3382.
Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383–3391.
Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721–6727.
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Tandem autologous versus single autologous transplantation followed by allogeneic hematopoietic cell transplantation for patients with multiple myeloma: results from the blood and marrow transplant clinical trials network (BMT CTN) 0102 trial. Lancet Oncol 2011; 12: 1195–2003.
Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandemautologous/reduced-intensity conditioning allogeneic stem-cell transplanttation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016–3022.
Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity conditioning allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.
Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562–567.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863–2869.
Festuccia M, Martino M, Ferrando F, Messica G, Moscato T, Fedele R et al. Allogeneic stemcell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther 2015; 15: 857–872.
Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 398–404.
Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia 2015; 29: 689–695.
Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia (e-pub ahead of print 6 October 2015; doi:10.1038/leu.2015.269).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Bruno, B. Allogeneic transplantation for multiple myeloma: yes, no or maybe?. Bone Marrow Transplant 51, 506–507 (2016). https://doi.org/10.1038/bmt.2016.12
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.12